Related Experiment Video
Updated: Feb 19, 2026
Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies
Serge Chooklin1, Serhii Chuklin2
1Surgical Center, Saint Paraskeva Medical Center, Lviv, Ukraine. chooklin_serge@hotmail.com.
Purpose:
To analyze current experimental and clinical studies regarding the role of calcium dysregulation in the pathogenesis of AP and to evaluate the efficacy of various pharmacological approaches to its correction.
Methods:
A literature review was conducted using PubMed, Scopus, and Google Scholar databases up to October 2025. Included were in vitro, in vivo, and clinical studies addressing the mechanisms of calcium imbalance in AP and the effects of different pharmacological agents targeting calcium regulation.
Results:
Key molecular targets for calcium-targeted therapy were identified, including IP3 and ryanodine receptors, SOC/CRAC channels, TMEM16A, the PI3K/Akt pathway, and the calcineurin/NFAT signaling cascade. Therapeutic compounds such as caffeine, dantrolene, docosahexaenoic acid (DHA), Orai1 channel inhibitors (CM4620/Auxora, GSK-7975A), TMEM16A inhibitors, insulin, calcium chelators (BAPTA-AM), calcineurin inhibitors (cyclosporin A, tacrolimus), and microRNAs (e.g., miR-26a) demonstrated the ability to reduce cytosolic calcium overload, suppress zymogen activation, stabilize mitochondrial function, and attenuate inflammation. Some of these agents are already used in other medical fields or are undergoing clinical trials as candidate treatments for AP.
Conclusions:
Pharmacological modulation of calcium homeostasis represents a promising pathogenetic approach to the treatment of acute pancreatitis. Existing evidence supports the need for further multicenter clinical studies to confirm the safety and efficacy of calcium-targeted strategies in routine clinical practice.
Insights
Calcium dysregulation is key in acute pancreatitis (AP). Targeting calcium pathways with drugs like dantrolene and Orai1 inhibitors shows promise for AP treatment, warranting further clinical studies.
Area of Science:
- Gastroenterology and Molecular Medicine
- Cellular Biology and Pharmacology
Background:
- Calcium dysregulation is a critical factor in the development of acute pancreatitis (AP).
- Understanding the molecular mechanisms of calcium imbalance is essential for developing effective treatments for AP.
Purpose of the Study:
- To review current research on calcium's role in AP pathogenesis.
- To assess the effectiveness of pharmacological interventions targeting calcium regulation in AP.
Main Methods:
- A comprehensive literature review of experimental and clinical studies was performed.
- Databases searched included PubMed, Scopus, and Google Scholar up to October 2025.
- Studies focused on calcium imbalance mechanisms and therapeutic agents in AP.
Main Results:
- Identified key targets: IP3 receptors, ryanodine receptors, SOC/CRAC channels, TMEM16A, PI3K/Akt, and calcineurin/NFAT pathways.
- Evaluated drugs like caffeine, dantrolene, DHA, Orai1 inhibitors, TMEM16A inhibitors, insulin, BAPTA-AM, cyclosporin A, tacrolimus, and miR-26a.
- These agents reduce calcium overload, suppress zymogen activation, stabilize mitochondria, and decrease inflammation.
Conclusions:
- Pharmacological correction of calcium homeostasis is a promising therapeutic strategy for AP.
- Further multicenter clinical trials are necessary to validate the safety and efficacy of these calcium-targeted treatments.
More Related Videos
10:39Preparation of Pancreatic Acinar Cells for the Purpose of Calcium Imaging, Cell Injury Measurements, and Adenoviral Infection
Published on: July 5, 2013
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...